Top ten cancers in men based on age-standardized rates per 100,000 person-years (ASR) and standardized rate ratio (SRR) in Fars province comparing to previous studies in Fars, GLOBOCAN 2008.

Top ten cancers in women based on age-standardized rates per 100,000 person-years (ASR) and standardized rate ratio (SRR) in Fars province comparing to previous studies in Fars, GLOBOCAN 2008.

In 2019, the age-standardized incidence rate of liver cirrhosis and other chronic liver diseases was over 29 cases per 100,000 men and around 21 cases per 100,000 women. This statistic displays the age-standardized incidence rate (ASR) of liver cirrhosis and other chronic liver diseases worldwide in 2019, by gender.

Age-standardized incidence rates (ASR) per 100,000 person years for each cancer, overall and by gender, from 1968 to 2012 in Singapore.

We have evaluated the ever changing epidemiology of cancers in Fars province, Iran since the re-establishment of Fars cancer registry. Based on the collected data from all related sources in Fars province from 2007–2010 we calculated the cancer age-standardized rates per 100,000 person-years (ASRs). The results are presented as incidence rates of cases by site according to the International Classification of Diseases for Oncology (ICD-O), sex, age, crude rate, and ASRs. In women the total ASR was 41.70 per 100,000 from 1985–1989 which had increased to 55.50 and 95.46 during 1998–2002 and 2007–2010. The incidence of breast cancer in women during 2007–2010 was about two and four times higher than 1998–2002 and 1985–1989. The incidence of colorectal cancer in women during 2007–2010 was about three and five times higher than 1998–2002 and 1985–1989. In men the total ASR was 62.9 per 100,000 in 1985–1989 that increased to 64.50 and 101.48 during 1998–2002 and 2007–2010. Although stomach cancer was the most common cancer among men during 1985–1989 and 1998–2002, but in recent study bladder cancer was the most common cancer among men in Fars province. The incidence of colorectal cancer in men during 2007–2010 was about three times higher than 1998–2002 and 1985–1989. This study shows growing incidence of cancer in southern Iran. The colorectal cancer in both genders had increased and its pattern is similar to western countries. In men, bladder and prostate cancers had a growing rate and the incidences of these cancers in the present study were greater than stomach cancer.

Unadjusted and standardized incidence rate (per 100,000 persons over 5 years) of breast cancer in Ho Chi Minh City (1996–2015) stratified by gender.

All-age numbers and ASR per 100,000 of incidence, prevalence, deaths, DALYs, YLDs and YLLs for ADD and total percentage change by sex in China, 1990-2021.

All-age numbers and ASR per 100,000 of incidence, prevalence, deaths, DALYs, YLDs and YLLs for ADD and total percentage change by sex globally, 1990-2021.

ObjectiveTo compare the incidence and survival rates of primary ovarian clear cell carcinoma (OCCC) and ovarian serous carcinoma (OSC) from a nationwide collected database.MethodsWe extracted information of patients with primary OCCC and OSC from the Korea Central Cancer Registry recorded between 1999 and 2018, including age at diagnosis and the Surveillance, Epidemiology, and End Results summary stage. Age-standardized incidence rates (ASRs) and annual percent changes (APCs) were calculated. Baseline characteristics and overall survival (OS) were compared between the OCCC and OSC groups.ResultsOverall, the incidence rate of primary OCCC increased markedly from 1999 (ASR, 0.16/100,000) to 2018 (0.76/100,000) (APC, 7.85%; P

BackgroundThe incidence of non-Hodgkin’s lymphoma (NHL) has increased steadily over the past few decades. Elucidating its global burden will facilitate more effective disease management and improve patient outcomes. We explored the disease burden, risk factors, and trends in incidence and mortality in NHL globally.MethodsThe up-to-date data on age-standardized incidence and mortality rates of NHL were retrieved from the GLOBOCAN 2020, CI5 volumes I-XI, WHO mortality database, and Global Burden of Disease (GBD) 2019, focusing on geographic disparities worldwide. We reported incidence and mortality by sex and age, along with corresponding age-standardized rates (ASRs), the average annual percentage change (AAPC), and future burden estimates to 2040.ResultsIn 2020, there were an estimated 545,000 new cases and 260,000 deaths of NHL globally. In addition, NHL resulted in 8,650,352 age-standardized DALYs in 2019 worldwide. The age-specific incidence rates varied drastically across world areas, at least 10-fold in both sexes, with the most pronounced increase trend found in Australia and New Zealand. By contrast, North African countries faced a more significant mortality burden (ASR, 3.7 per 100,000) than highly developed countries. In the past decades, the pace of increase in incidence and mortality accelerated, with the highest AAPC of 4.9 (95%CI: 3.6-6.2) and 6.8 (95%CI: 4.3-9.2) in the elderly population, respectively. Considering risk factors, obesity was positively correlated with age-standardized incidence rates (P< 0.001). And North America was the high-risk region for DALYs due to the high body mass index in 2019. Regarding demographic change, NHL incident cases are projected to rise to approximately 778,000 by 2040.ConclusionIn this pooled analysis, we provided evidence for the growing incidence trends in NHL, particularly among women, older adults, obese populations, and HIV-infected people. And the marked increase in the older population is still a public health issue that requires more attention. Future efforts should be directed at cultivating health awareness and formulating effective and locally tailored cancer prevention strategies, especially in most developing countries.

BackgroundTo explore the geographical pattern and temporal trend of autism spectrum disorders (ASD) epidemiology from 1990 to 2019, and perform a bibliometric analysis of risk factors for ASD.MethodsIn this study, ASD epidemiology was estimated with prevalence, incidence, and disability-adjusted life-years (DALYs) of 204 countries and territories by sex, location, and sociodemographic index (SDI). Age-standardized rate (ASR) and estimated annual percentage change (EAPC) were used to quantify ASD temporal trends. Besides, the study performed a bibliometric analysis of ASD risk factors since 1990. Publications published were downloaded from the Web of Science Core Collection database, and were analyzed using CiteSpace.ResultsGlobally, there were estimated 28.3 million ASD prevalent cases (ASR, 369.4 per 100,000 populations), 603,790 incident cases (ASR, 9.3 per 100,000 populations) and 4.3 million DALYs (ASR, 56.3 per 100,000 populations) in 2019. Increases of autism spectrum disorders were noted in prevalent cases (39.3%), incidence (0.1%), and DALYs (38.7%) from 1990 to 2019. Age-standardized rates and EAPC showed stable trend worldwide over time. A total of 3,991 articles were retrieved from Web of Science, of which 3,590 were obtained for analysis after removing duplicate literatures. “Rehabilitation”, “Genetics & Heredity”, “Nanoscience & Nanotechnology”, “Biochemistry & Molecular biology”, “Psychology”, “Neurosciences”, and “Environmental Sciences” were the hotspots and frontier disciplines of ASD risk factors.ConclusionsDisease burden and risk factors of autism spectrum disorders remain global public health challenge since 1990 according to the GBD epidemiological estimates and bibliometric analysis. The findings help policy makers formulate public health policies concerning prevention targeted for risk factors, early diagnosis and life-long healthcare service of ASD. Increasing knowledge concerning the public awareness of risk factors is also warranted to address global ASD problem.

BackgroundGaps remained in the updated information of the firearm violence (FV) burden from a global landscape. Understanding the global burden of FV could contribute to decision-making.MethodsData on the FV burden, including physical violence by firearm (PVF), self-harm by firearm (SHF), and unintentional firearm injuries (UFI), were extracted from the Global Burden of Disease 2019. The temporal trends of age-standardized rate (ASR) were estimated using estimated annual percentage change (EAPC).ResultsIn 2019, PVF, SHF, and UFI reported 710.64 × 103, 335.25 × 103, and 2,133.88 × 103, respectively, incident cases worldwide. Their ASR (/100,000 people-years) were 9.31, 4.05, and 28.07. During 1990–2019, the overall incident ASRs of PVF presented an increasing trend (EAPC = 0.61, 95% confidence interval [CI]: 0.48 to 0.75). Notably, pronounced increasing trends were observed in Tropical Latin America, and North Africa and Middle East. However, incident trends of SHF and UFI declined globally, with the respective EAPCs being −0.68 (95% CI: −0.83 to −0.54) and −0.98 (95% CI: −1.19 to −0.77). In 2019, the ASR of death due to PVF, SHF, and UFI were 2.23, 0.65, and 0.26, and that of DALYs were 127.56, 28.10, and 17.64, respectively. Decreasing trends in the ASRs of FV were observed in most regions and countries worldwide over the past three decades, particularly that of PVF in Estonia.ConclusionThe FV burden was heterogeneous across regions and countries, which was deeply subjected to socioeconomic factors. The findings highlighted that specific prevention strategies and interventions were required, particularly in the high prevalent settings.

Projecting the burden of thyroid cancer (TC) over time provides essential information to effectively plan measures for its management and prevention. This research obtained data from the Global Burden of Disease (GBD) Study from between 1990 and 2019 to model how TC will affect China until 2039 by conducting the Bayesian age-period-cohort analysis. The number of new TC cases in China was 10,030 in 1990, 39,080 in 2019, and is projected to be 47,820 in 2039. This corresponds to 3,320, 7,240, and 4,160 deaths, respectively. Disability-adjusted life years (DALYs) cases increased from 103,490 in 1990 to 187,320 in 2019. The age-standardized rate (ASR) of incidence increased from 1.01 to 2.05 during 1990-2019 and was projected to increase to 3.37 per 100,000 person-years until 2039. The ASR of mortality (ASMR) remained stable during the study period and was projected to have a mild decline from 0.39 to 0.29/100,000 during 2020-2039. Although the ASMR in male patients has maintained increasing at a rate of 2.2% per year over the past 30 years, it is expected to decline at a rate of 1.07% per year in 2019-2039. The most significant increase in crude incidence occurred in people aged 45-65 from 1990 to 2019, however, this will shift into young people aged 10-24 from 2020 to 2039. In addition, the proportion of deaths and DALYs caused by obesity increased from 1990 to 2019 and affected men more than women. In conclusion, a substantial increase in counts of incidence of TC in China is projected over the next two decades, combined with the slightly declining mortality, indicating that rational health policies are needed in the future to cope with the increasing number of TC patients, especially among males and adolescents.

BackgroundBreast cancer associated with high red meat consumption has become a significant global health issue. This study aims to analyze the global and regional disease burden related to breast cancer attributable to high red meat diets from 1990 to 2021, and to predict future trends in disease burden through 2030, providing scientific evidence for the development of targeted public health strategies.MethodsData were extracted from the Global Burden of Disease (GBD) database, focusing on breast cancer-related attribution indicators, including the age-standardized rates (ASRs) of mortality, years of life lost (YLLs), years lived with disability (YLDs). The study analyzed the changes in breast cancer disease burden associated with high red meat consumption from 1990 to 2021 at the global level, across 21 regions, and in 204 countries. Future trends were projected using the Bayesian Age-Period-Cohort (BAPC) model.ResultsIn 2021, breast cancer deaths attributable to excessive red meat diets totaled 81,506, with YLLs amounting to 2,135,620 person-years and YLDs accounting for 214,442 person-years. These values represent increases of 80.83, 72.69, and 65.37%, respectively, compared to 1990. Despite global decreases in the ASRs of mortality and YLLs (which decreased to 1.15/100,000 and 30.12/100,000, with EAPCs of −0.77 and −0.73, respectively), the ASR of YLDs remained relatively stable (EAPC of −0.12). Stratification by Socio-Demographic Index (SDI) revealed a significant decline in disease burden in high-SDI regions, while the ASR in low-SDI regions trended upward. Projections suggested that by 2030, the global ASR of breast cancer burden may stabilize, while the burden in low-SDI regions is expected to continue rising.ConclusionFrom 1990 to 2021, the global age-standardized rate of the breast cancer disease burden decreased, but disparities between regions with different SDI levels remain a major challenge. In the future, it is essential to prioritize addressing the burden in low-SDI regions and developing targeted interventions to optimize health resources, thereby mitigating the public health threat of breast cancer.

AbstractBackground:Managing acute myocardial infarction (AMI) in patients with chronic kidney disease (CKD) or end-stage renal disease on dialysis (renal replacement therapy, RRT) presents challenges due to elevated complication risks. Concerns about contrast-related kidney damage may lead to the omission of guideline-directed therapies like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in this population.Methods:We analyzed German-DRG data of 2016 provided by the German Federal Bureau of Statistics (DESTATIS). We included cases with a primary diagnosis of AMI (ST-Elevation Myocardial Infarction (STEMI) or Non-ST-Elevation Myocardial Infarction (NSTEMI) ICD-10: I21 or I22) with and without CKD or RRT. We calculated crude- and age-standardized hospitalization rates (ASR, per 100,000 person years). Furthermore, we calculated log-binominal regression models adjusting for sex, CKD, RRT, comorbidities, and place of residence to estimate adjusted relative-risks (aRR) for receiving treatments of interest in AMI, such as PCI or CABG.Results:We identified 69,728 STEMI-cases and 147,786 NSTEMI-cases. STEMI-cases without CKD had percutaneous coronary intervention (PCI) in 80.1%. In contrast, STEMI-cases with CKD or RRT had PCI in 69.7% and 71.2%, respectively. The ASR for STEMI-cases amounted to 62.3 (95%CI 61.8-62.8) per 100,000 person years, whereas the ASR for NSTEMI-cases was 122.4 (95%CI 121.7-123.0) per 100,000 person years. In regression analysis AMI-cases with CKD were less likely treated with PCI (aRR: 0.89 (95%CI 0.88-0.90)), compared to cases without CKD. AMI-Cases with RRT showed no difference in PCI rates (aRR: 1.0 (95%CI 0.97-1.03)) but were more frequently treated with CABG (aRR: 2.20 (95%CI 2.03-2.39)). Conversely, CKD was negatively associated with CABG (aRR: 0.71, 95%CI 0.67-0.75) when non-CKD cases were used as the reference group.Conclusion:We show that AMI-cases with CKD underwent PCI less frequently, while RRT has no discernible impact on PCI utilization in AMI. Furthermore, AMI-cases with RRT exhibited a higher CABG rate.

• Joinpoint is significantly different from zero at alpha = 0.05;† ASR – Age Standardized Rate (per 100 000, using World standard population);‡ Average Annual Percent Change;§ CI − Confidence Interval;** Joinpoint results are not shown for this age subgroup, since there were less than 5 cases in any given year. Abbreviations: HL (Hodgkin's lymphoma), NHL (Non-Hodgkin's lymphoma), MM (Multiple myeloma), LL (Lymphoid leukemia), ML (Myeloid leukemia).†† Three joinpoints, for HL trend in overall: Trend 1 (1991–1993): annual percent change (APC) (95% CI) = +19.7 (−2.1 to 46.4); Trend 2 (1993–1999): APC (95% CI) = −9.3* (−13.3 to −5.1); Trend 3 (1999–2002): (APC) (95% CI) = +12.2 (−8.2 to 37.2); Trend 4 (2002–2010): (APC) (95% CI) = −3.4* (−5.5 to −1.2).‡‡ One joinpoint, for leukemia trend in overall: Trend 1 (1991–1998): (APC) (95% CI) = −2.2 (−4.4 to 0.1); Trend 2 (1998–2010): APC (95% CI) = +1.3* (0.3 to 2.3).§§ One joinpoint, for ML trend in overall: Trend 1 (1991–1999): (APC) (95% CI) = −3.1* (−6.0 to −0.1); Trend 2 (1999–2010): APC (95% CI) = +4.9* (2.9 to 6.9).†‡ One joinpoint, for NHL trend in 70+ years old persons: Trend 1 (1991–1995): (APC) (95% CI) = −9.7 (−22.5 to 5.2); Trend 2 (1995–2010): APC (95% CI) = +7.3* (5.1 to 9.5).†§ Two joinpoints, for all leukemia trend in 70+ years old persons: Trend 1 (1991–1993): annual percent change (APC) (95% CI) = −29.9 (−57.0 to 14.5); Trend 2 (1993–1996): APC (95% CI) = +25.9 (−22.9 to 105.6); Trend 3 (1996–2010): (APC) (95% CI) = −0.3 (−2.6 to 2.0).‡§ One joinpoint, for LL trend in 70+ years old persons: Trend 1 (1991–1996): (APC) (95% CI) = −4.5 (−11.1 to 2.6); Trend 2 (1996–2010): APC (95% CI) = +4.3* (2.8 to 5.9).§† One joinpoint, for ML trend in 60–69 years old persons: Trend 1 (1991–2000): (APC) (95% CI) = −3.0 (−6.0 to 0.2); Trend 2 (2000–2010): APC (95% CI) = +7.6* (4.6 to 10.6).Joinpoint regression analysis* (of age-specific and age-standardized rates) of malignant lymphatic and hematopoietic neoplasms mortality rates per 100,000 persons in Serbia, excluding the Autonomous Province of Kosovo and Metohia, by type and age, in 1991–2010 period.

IntroductionSub-Saharan Africa (SSA) is plagued by myriads of diseases, mostly infectious; but cancer disease burden is rising among non-communicable diseases. Nigeria has a high burden of cancer, however its remote underserved culturally-conserved populations have been understudied, a gap this study sought to fill.MethodsThis was a cross-sectional multi-institutional descriptive study of histologically diagnosed cancers over a four-year period (January 2019-December 2022) archived in the Departments of Pathology and Cancer Registries of six tertiary hospitals in the northeast of Nigeria. Data obtained included age at diagnosis, gender, tumor site and available cancer care infrastructure. Population data of the study region and its demographics was obtained from the National Population Commission and used to calculate incident rates for the population studied.ResultsA total of 4,681 incident cancer cases from 2,770 females and 1,911 males were identified. The median age at diagnosis for females was 45 years (range 1–95yrs), and 56 years (range 1–99yrs) for males. Observed age-specific incidence rates (ASR) increased steadily for both genders reaching peaks in the age group 80 years and above with the highest ASR seen among males (321/100,000 persons) compared to females (215.5/100,000 persons). Breast, cervical, prostatic, colorectal and skin cancers were the five most common incident cancers. In females, breast, cervical, skin, ovarian and colorectal cancers were the top five malignancies; while prostate, haematolymphoid, skin, colorectal and urinary bladder cancers predominated in men.ConclusionRemote SSA communities are witnessing rising cancer disease burden. Proactive control programs inclusive of advocacy, vaccination, screening, and improved diagnostics are needed.

Annual rates, total rates, gender-specific rates and age-specific incidence rates in age groups (AG) per one year.